Premium
Treatment of Helicobacter pylori Infection 2011
Author(s) -
O’Connor Anthony,
Gisbert Javier P.,
McNamara Deirdre,
O’Morain Colm
Publication year - 2011
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1523-5378.2011.00881.x
Subject(s) - helicobacter pylori infection , helicobacter pylori , medicine , helicobacter infections , microbiology and biotechnology , biology
This article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first‐line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first‐line eradication of H. pylori . In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first‐line therapy. The sequential and “concomitant” regimes have also been studied in new settings and may have a role in future algorithms also. In addition, data have emerged that the probiotic Saccharomyces boulardii may be a useful adjunct to antibiotic therapy. Other studies promote individualized therapies based on host polymorphisms, age, and other such demographic factors.